Support

Taltz together logo

Taltz Together is here to provide the resources and support your patients need. For assistance, call 1-844-TALTZ-NOW (1-844-825-8966) or enroll your patients in Taltz Together by completing the Adult Dermatology Enrollment Form, Pediatric Dermatology Enrollment Form, or Rheumatology Enrollment Form.


Offerings include:

Taltz support insurance

Insurance Investigation

  • Help with preliminary insurance investigation and specialty pharmacy identification
Support injection training

Injection Training

  • Free of charge to patients and their families
  • Injection training videos available here
Ongoing support

Ongoing Support

  • A personal patient resource to help answer questions or concerns
  • Help is available Monday-Friday from 8 AM to 10 PM ET
Support field reimbursement

Field Reimbursement Support

The Field Reimbursement Manager is an experienced access professional who can help your patients navigate the complex access and reimbursement environment

The managers are

  • Knowledgeable: understand Taltz Together services, access challenges, and affordability options
  • Connected: integrated with the Taltz Together call center and understand the Taltz contracted specialty pharmacy network
  • Patient Focused: committed to providing information to support patient access to Taltz
Support sharps

Sharps Disposal Support

Allows patients to safely dispose of Taltz devices. Once the container is full, your patients can mail it back and contact Taltz Together to receive another one

For more information about Lilly’s privacy practice, please view the Privacy Statement.

What are the steps to start a patient on Taltz?

Start with a Taltz Together Enrollment Form, which serves as the Taltz prescription

1. Depending on your office workflow, decide where the Taltz prescription will be sent.

Your options include:

A. Send the prescription to Taltz Together directly.

B. Send the prescription to a specialty pharmacy of your choice. You can find the list of the enhanced specialty pharmacy network partners here.

Declare your selection on theTaltz Together Enrollment Form.

2. Complete the Taltz Together Enrollment Form and have your patient sign it.

If the patient leaves the office without signing the enrollment form, have them call Taltz Together or go online taltz.com to get their Taltz Savings Card.

3. When discussing initiation of Taltz treatment with your patient, be sure to instruct them to answer the phone to schedule Taltz shipment. Remind your patient to call Taltz Together should they have any questions or concerns about access or treatment cost.

4. Fax the Taltz Together Enrollment Form to Taltz Together (1-844-344-8108).

If sending the prescription to a specialty pharmacy, fax the completed Taltz Together Enrollment Form to Taltz Togetherand the specialty pharmacy.

Indications and Important Safety Information
Indications

Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Important Safety Information
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.
IX HCP ISI 07MAY2020